Bacil Pharma Statistics

Total Valuation

Bacil Pharma has a market cap or net worth of INR 596.37 million. The enterprise value is 569.43 million.

Market Cap	596.37M
Enterprise Value	569.43M

Important Dates

The last earnings date was Monday, May 12, 2025.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Bacil Pharma has 14.35 million shares outstanding. The number of shares has decreased by -0.82% in one year.

Current Share Class	14.35M
Shares Outstanding	14.35M
Shares Change (YoY)	-0.82%
Shares Change (QoQ)	+32.51%
Owned by Insiders (%)	6.35%
Owned by Institutions (%)	n/a
Float	12.48M

Valuation Ratios

The trailing PE ratio is 60.22.

PE Ratio	60.22
Forward PE	n/a
PS Ratio	90.17
PB Ratio	2.35
P/TBV Ratio	2.35
P/FCF Ratio	n/a
P/OCF Ratio	148.79
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	140.91
EV / Sales	86.10
EV / EBITDA	139.46
EV / EBIT	139.70
EV / FCF	n/a

Financial Position

The company has a current ratio of 17.21, with a Debt / Equity ratio of 0.01.

Current Ratio	17.21
Quick Ratio	16.92
Debt / Equity	0.01
Debt / EBITDA	0.40
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 3.03% and return on invested capital (ROIC) is 1.89%.

Return on Equity (ROE)	3.03%
Return on Assets (ROA)	1.89%
Return on Invested Capital (ROIC)	1.89%
Return on Capital Employed (ROCE)	1.60%
Revenue Per Employee	2.20M
Profits Per Employee	1.35M
Employee Count	3
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +107.90% in the last 52 weeks. The beta is 0.31, so Bacil Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.31
52-Week Price Change	+107.90%
50-Day Moving Average	41.59
200-Day Moving Average	36.57
Relative Strength Index (RSI)	50.37
Average Volume (20 Days)	32,432

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bacil Pharma had revenue of INR 6.61 million and earned 4.04 million in profits. Earnings per share was 0.69.

Revenue	6.61M
Gross Profit	6.61M
Operating Income	4.08M
Pretax Income	4.08M
Net Income	4.04M
EBITDA	4.08M
EBIT	4.08M
Earnings Per Share (EPS)	0.69

Full Income Statement

Balance Sheet

The company has 28.57 million in cash and 1.64 million in debt, giving a net cash position of 26.93 million or 1.88 per share.

Cash & Cash Equivalents	28.57M
Total Debt	1.64M
Net Cash	26.93M
Net Cash Per Share	1.88
Equity (Book Value)	254.31M
Book Value Per Share	32.60
Working Capital	27.39M

Full Balance Sheet

Cash Flow

Operating Cash Flow	4.01M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of 61.63% and 61.10%.

Gross Margin	100.00%
Operating Margin	61.63%
Pretax Margin	61.61%
Profit Margin	61.10%
EBITDA Margin	61.73%
EBIT Margin	61.63%
FCF Margin	n/a

Dividends & Yields

Bacil Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.82%
Shareholder Yield	n/a
Earnings Yield	0.68%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a